Hemgenix
Payments companies reported to CMS as associated with Hemgenix. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Hemgenix, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Hemgenix
These are the largest totals companies reported as associated with Hemgenix. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Richard Lemons | Salt Lake City, UT | Pediatric Hematology-Oncology | $511,358.97 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $285,844.01 |
| Doris Quon | Los Angeles, CA | Hematology (Internal Medicine) | $196,219.42 |
| Tammuella Chrisentery-Singleton | New Orleans, LA | Pediatric Hematology-Oncology | $99,578.22 |
| Steven Pipe | Ann Arbor, MI | Pediatric Hematology-Oncology | $88,846.84 |
| Maissaa Janbain | New Orleans, LA | Hematology & Oncology | $83,246.06 |
| Beverly Schaefer | Buffalo, NY | Pediatric Hematology-Oncology | $82,845.47 |
| Michael Recht | New Haven, CT | Pediatric Hematology-Oncology | $57,933.44 |
| Lynn Malec | Milwaukee, WI | Pediatric Hematology-Oncology | $55,059.87 |
| Annette Von Drygalski | San Diego, CA | Hematology & Oncology | $24,011.90 |
Prescribed Hemgenix?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.